• Home
The News Universe
No Result
View All Result
No Result
View All Result
The News Universe
No Result
View All Result

ProBio is now licensing the CHOK1 cell line development system to biopharma companies for commercial use

admin by admin
December 12, 2024
in Uncategorized
0

CHOK1-GenS&CHOK1-ADCC+

Cell Line Development System Commercial License

ProBio has 12 years of experience in mammalian cell line development, and is one of the earliest companies getting the CHO-K1 – CHO commercial license for commercial use and sublicense agreement from ECACC.

ProBio has two cell line development systems: wild-type cell line CHOK1-GenS and ADCC-enhanced cell line CHOK1-ADCC +. CHOK1-GenS cell line development system without chemical . Developed ADCC enhanced host cell line (CHOK1-ADCC+), which can produce afucosylated monoclonal antibodies with enhanced ADCC activity. They are in together with the high-expression proprietary pGenHT 1.0-UP vector, the average titer of mAb is 5.7 g/L, the maximum titer of mAb is up to 15 g/L.

CHOK1 system exclusive advantages

IP Clear

• ECACC license agreement• Proprietary pGenHT 1.0-UP vector

Royalty Free

• One-time payment without royalty

2 CHO-K1 Host Cell License to Choose

• Wide type CHOK1-GenS• ADCC enhanced CHOK1-ADCC+

Combo license at discounted price

• Purchase in combination with wild type CHOK1-GenS cell line, and get a discounted price

Suitable for different type of proteins

• mAb/Protein

• BsAb,etc

Fulfill the regulatory requirements

• Fulfill the regulatory requirements of FDA,EMA and NMPA

Case Study of CHOK1-GenS cell line system

High productivity with CHOK1-GenS system

  • Suitable for different type of molecules

 Excellent stability with CHOK1-GenS system

  • The titer at the end of stability study during fed-batch is recorded as T2.
  • The titer at the beginning of stability study during fed-batch is recorded as T1.
  • Titer variation=(T2-T1)/T1*100%
  • Titer variation should be within 30%.

 

High productivity with CHOK1-GenS system

Titer prior to cell culture up to 15 g/L

Excellent Stability in Scale-Up from 3L to 200L

Case Study of CHOK1-ADCC+ cell line system

CD16a 158V/F affinity (BLI)

The affinity to CD16a (158V and 158F) was increased by 3-4 times.

PBMC-based ADCC

  • Cytotoxicity is increased by about 10%.
  • Effect concentration (EC50) was reduced by 6 times.
  • ADCC effect was significantly enhanced.

CHOK1 delivery package

Media Contact
Company Name: ProBio CDMO
Email: Send Email
Phone: 1-877-436-7274 (Toll-Free)
Country: United States
Website: https://www.probiocdmo.com

Previous Post

Nuance Energy Revolutionizes Solar Installation with Innovative Racking Solutions

Next Post

The Binary Holdings secures $5 Million from ABO Digital to Fuel Expansion of their Decentralized Network Towards One Billion Users by 2025

Next Post

The Binary Holdings secures $5 Million from ABO Digital to Fuel Expansion of their Decentralized Network Towards One Billion Users by 2025

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.

No Result
View All Result

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.